OMNIlife science to Exhibit at American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas March 25 - 27

EAST TAUNTON, Mass., March 18, 2015 /PRNewswire/ -- OMNIlife science^TM, Inc. ("OMNI^TM"), an established medical technology company targeting the $15 billion global hip and knee replacement device market, announced it will exhibit its' robotic assisted total knee replacement system, computer assisted total hip replacement technology, and line of implants at the American Academy of Orthopaedic Surgeons Meeting (AAOS) hosted at the Venetian/Sands EXPO in Las Vegas in Booth #2631. OMNI is a proud participant of the meeting.

Rick Randall, President and Chief Executive Officer of OMNI, said, "We look forward to exhibiting at the AAOS, especially in light of recently released market research that indicates approximately 40% of U.S. orthopedic surgeons expect that robotics will eventually become standard of care in hip/knee procedures." 

OMNI offers the only commercially available robotic total knee replacement technology in the US. Since its introduction, more than 5,000 procedures have been performed world-wide.  The technology allows the surgeon to optimize implant placement specific to the needs of the patient's anatomy and supports the execution of the procedure with precision, accuracy and reproducibility. 

"Providing surgeons a technology that records the precision and reproducibility of the joint replacement may allow the hospital and physician to demonstrate a quality measure important to patients and insurers." stated Rick Randall. 

The American Academy of Orthopaedic Surgeons provides education and practice management services for orthopaedic surgeons and allied health professionals. The Academy also serves as an advocate for improved patient care and informs the public about the science of orthopaedics. The not-for-profit organization has grown to the world's largest medical association of musculoskeletal specialists. The Academy now serves more than 36,000 members worldwide.  More than 10,000 orthopedic surgeons, fellows, residents and allied health professionals are expected to attend the 2105 annual meeting.

About OMNIlife science, Inc. (OMNI)

OMNI is a privately held company with a proprietary robotic assisted total knee replacement platform which allows surgeons to conduct patient specific total knee surgery designed to enhance patient satisfaction, reduce hospital costs, and remove need for MRI and x-rays.  This technology provides surgeons the much needed option to adjust during the procedure and is designed to provide an accurate customized fit.  OMNI is an innovative and well-established hip and knee implant replacements engineering, manufacturing and distribution support company and is focused on providing cutting edge technologies to improve patient care.

Forward-Looking Statements

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., (OMNI) including its advance robotic plans and statements using the terms "plans," "confident" or similar expressions are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI's markets, decrease in the demand for OMNI's products, delays in OMNI's product research and development cycles, decreases in the use of OMNI's principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI's current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI's current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI's sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI's products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward looking statements after the date of this press release

Contact:

OMNIlife science, Inc. (OMNI)
Kirsten Wyzanski
Director
774.226.1892

SOURCE OMNIlife science, Inc.

Related Links

http://www.omnils.com